Post, “Trust me, I’m a Doctor”, is not an attack on biotech stock Calzada

In the previous post, I did not seek to impugn any particular party, but to
point out how easy it is for folk of undoubted integrity, with a desire
to do the right thing, such as the Essendon Football Club, to be
wrong-footed, often because of poor medical advice. In addition they received documented approval from ASADA, Australia’s anti-doping authority to use the peptide derived from Human Growth Hormone.

Essentially the debate should be a medical one, decided
through medical evaluation of the product in question. There is genuine
doubt whether AOD-9604 does have the clinical efficacy of the
banned parent, Human Growth Hormone.

Those trials conducted by Professor Wittert and funded by Metabolic
Pharmaceuticals were negative both as an anti-obesity treatment, and for
an anabolic activity in increasing muscle bulk.

As pointed out the most recent research, carried out in Mt Sinai
Hospital
in Toronto Canada in 2011 and 2012 was in-vitro, not a clinical
trial
. Their conclusions were that the drug stimulated
bone growth, and assisted in cartilage and muscle repair.

Calzada‘s website indicates that they have sought partners and
licensing interest for the use of AOD-9604; they have also received approval
for marketing in a variety of forms in the USA  via direct sales (OTC).  Calzada may not have manufactured itself the many products now available online, but as developer of AOD-9604, have they received royalties? I do not allege any unlawful, or even unethical behaviour by $CZD. Indeed I think they have acted responsibly in financing medically unbiased trials of the drug.

What I do wish to point out is that in common with many biotech companies, there is a tendency to exaggerate the benefit of pharmaceutical products for commercial gain, and in this the medical team may sense an obligation to find positive results in the clinical trials.

Essendon Football Club

Essendon Football Club (Photo credit: Wikipedia)

Failing this companies may seek to market the product anyway.
In doing so they need to be particularly careful not to resort to
dishonest advertising claims. It is questionable whether advertising should be permitted for products of
dubious benefit. 

About Kenneth Robson

I studied at Adelaide Boys' High School, and the University of Adelaide, Medical School. graduating in 1961. My field of specialisation was Plastic and Reconstructive Surgery. Prior to establishing my practice in Adelaide, I spent 5 years working in India, and Papua-New Guinea, in the field of reconstructive surgery for leprosy. In retirement I joined the Australian Technical Analyst Association and passed the two examinations for a Diploma inTechnical Analysis, and the designation Certified Financial Technician (CFTe) by the International Federation of Technical Analysts.
This entry was posted in Community Issues and tagged , , , , , , , . Bookmark the permalink.